非肌层浸润性膀胱癌膀胱灌注治疗相关下尿路症状的管理趋势分析
本研究基于Merative™ MarketScan®商业数据库(2016-2024)开展回顾性队列研究,纳入2978例接受膀胱内卡介苗或化疗的非肌层浸润性膀胱癌患者,评估诱导治疗后180天内下尿路症状治疗的利用情况。结果显示29.6%的患者接受了下尿路症状治疗,以α受体阻滞剂(19.9%)和抗胆碱能药物(13.7%)为主,β-3激动剂(1.3%)和非药物治疗几乎未被使用;接受下尿路症状治疗与诱导治疗完成率较低(75.9% vs. 79.0%,P=0.049)及膀胱切除术比例较高(14.8% vs. 11.9%,P=0.021)相关。
要点
- 近三分之一膀胱灌注治疗患者需药物干预下尿路症状,但β-3激动剂和非药物治疗几乎未使用。
- 下尿路症状治疗与诱导治疗完成率较低及膀胱切除术比例较高相关。
- 需进一步研究先进疗法以改善患者依从性和肿瘤学结局。
核心结论
- 近三分之一接受膀胱灌注治疗的膀胱癌患者需下尿路症状药物治疗,但β-3激动剂和非药物治疗几乎完全未被使用。
- 下尿路症状与诱导治疗未完成相关,需进一步研究先进疗法以改善依从性和肿瘤学结局。
研究设计与样本
- 回顾性队列研究,使用Merative™ MarketScan®商业数据库(2016-2024)。
- 纳入2978例接受膀胱内卡介苗或化疗的膀胱癌患者。
主要发现
- 2978例患者中29.6%接受了下尿路症状治疗。
- α受体阻滞剂使用率19.9%,抗胆碱能药物13.7%,β-3激动剂1.3%。
- 非药物治疗极少:0.3%接受肉毒毒素注射,无患者接受骶神经调节或经皮胫神经刺激。
- 下尿路症状治疗与诱导治疗完成率较低相关(75.9% vs. 79.0%,P=0.049)。
- 下尿路症状治疗与膀胱切除术比例较高相关(14.8% vs. 11.9%,P=0.021)。
临床怎么用
- 临床应关注膀胱灌注治疗患者的下尿路症状管理,目前以α受体阻滞剂和抗胆碱能药物为主。
- 可考虑评估β-3激动剂和非药物治疗在适合患者中的应用潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the utilization of oral pharmacotherapy and minimally invasive non-pharmacologic treatments approved for overactive bladder among patients receiving intravesical therapy for non-muscle invasive bladder cancer, as this treatment is frequently complicated by lower urinary tract symptoms, which are associated with treatment discontinuation and worse oncological outcomes. METHODS: We conducted a retrospective cohort study using the Merative™ MarketScan® Commercial Database (2016-2024). We identified patients with bladder cancer receiving intravesical bacillus Calmette-Guérin or chemotherapy. The primary outcome was the receipt of lower urinary tract symptom therapy-oral pharmacotherapy (anticholinergics, β-3 agonists, alpha blockers) or minimally invasive non-pharmacologic treatments (botulinum toxin injection, sacral neuromodulation, percutaneous tibial nerve stimulation)-in the 180 days after initiating induction therapy. RESULTS: Among 2978 patients, 29.6% received lower urinary tract symptom therapy. Use of alpha blockers (19.9%) and anticholinergics (13.7%) predominated. Use of β-3 agonists (1.3%) or non-pharmacologic treatments was exceedingly rare: only 0.3% received botulinum toxin injection, and no patients received sacral neuromodulation or percutaneous tibial nerve stimulation. Lower urinary tract symptom therapy was associated with a lower proportion of patients completing induction therapy (75.9% vs. 79.0%) (P=0.049) and higher proportion of patients undergoing cystectomy (14.8% vs. 11.9%) (P=0.021). CONCLUSION: While nearly one-third of bladder cancer patients require pharmacotherapy for lower urinary tract symptoms during intravesical treatment, β-3 agonists and non-pharmacologic treatments are almost entirely unutilized. Given the association between lower urinary tract symptoms and induction therapy non-completion, further research into these advanced therapies is warranted to improve patient adherence and oncologic outcomes.
引用
- Tallman JE, Hyman MJ, Agarwal PK, et al. Analyzing Trends in Management of Intravesical Therapy-Associated Lower Urinary Tract Symptoms for Patients Treated for Non-muscle Invasive Bladder Cancer. Urology. 2026. PMID: 42854855. doi:10.1016/j.urology.2026.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。